142,351 Shares in Teva Pharmaceutical Industries Limited (NYSE:TEVA) Acquired by Fred Alger Management LLC

Fred Alger Management LLC acquired a new stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 142,351 shares of the company’s stock, valued at approximately $2,565,000.

A number of other large investors have also recently bought and sold shares of TEVA. UMB Bank n.a. raised its stake in shares of Teva Pharmaceutical Industries by 555.6% during the 3rd quarter. UMB Bank n.a. now owns 2,439 shares of the company’s stock valued at $44,000 after buying an additional 2,067 shares during the last quarter. Smithfield Trust Co boosted its position in Teva Pharmaceutical Industries by 55.7% in the 3rd quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock worth $50,000 after purchasing an additional 980 shares in the last quarter. Byrne Asset Management LLC purchased a new position in shares of Teva Pharmaceutical Industries during the 2nd quarter valued at approximately $52,000. Claro Advisors LLC purchased a new stake in Teva Pharmaceutical Industries during the third quarter worth $52,000. Finally, GAMMA Investing LLC grew its position in Teva Pharmaceutical Industries by 105.7% during the second quarter. GAMMA Investing LLC now owns 3,388 shares of the company’s stock valued at $55,000 after buying an additional 1,741 shares during the period. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on TEVA. StockNews.com upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 17th. Barclays lifted their price target on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the company an “overweight” rating in a research note on Wednesday, October 23rd. UBS Group upped their price objective on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. Finally, JPMorgan Chase & Co. boosted their target price on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research note on Monday, October 21st. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $19.67.

Teva Pharmaceutical Industries Stock Up 1.3 %

Shares of TEVA opened at $16.78 on Monday. Teva Pharmaceutical Industries Limited has a 52-week low of $9.35 and a 52-week high of $19.31. The company has a quick ratio of 0.61, a current ratio of 0.89 and a debt-to-equity ratio of 2.57. The stock has a fifty day simple moving average of $17.56 and a two-hundred day simple moving average of $17.35. The company has a market capitalization of $19.01 billion, a PE ratio of -19.74, a price-to-earnings-growth ratio of 1.30 and a beta of 0.87.

Insider Activity at Teva Pharmaceutical Industries

In related news, EVP Christine Fox sold 19,388 shares of the company’s stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total value of $327,075.56. Following the transaction, the executive vice president now directly owns 44,104 shares in the company, valued at approximately $744,034.48. This represents a 30.54 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 0.55% of the stock is currently owned by insiders.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.